Here, we characterized the therapeutic functions of the monoclonal antibody CR3022 that binds to a conserved site on the RBD that is not fully blocked in the presence of ACE2, offering therapeutic benefit even after infection has been initiated. This evidence concerns the gene ACE2 and infection.